Bevacizumab News and Research

RSS

Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.

Glioblastoma multiforme responds to new treatment

One of the toughest cancers to treat effectively is glioblastoma multiforme (GBM), the most common form of primary brain cancer.

28 Feb 2008

Researchers explain why Avastin can cause potentially fatal brain inflammation

New research by scientists at Schepens Eye Research Institute may help explain why the anti-cancer drug Avastin, which targets a growth factor responsible for creation of new blood vessels, causes potentially fatal brain inflammation in certain patients.

14 Feb 2008

Avastin cancer drug does well in breast cancer study

A new study on the cancer drug Avastin has found that when the drug is combined with chemotherapy it slowed down the progression of breast cancer.

13 Feb 2008

Avastin (bevacizumab) damages brain vessels

The cancer drug Avastin (bevacizumab) is used to treat advanced bowel cancer in combination with chemotherapy.

12 Feb 2008

Study shows that antiangiogenic agent delays progression of advanced breast cancer

The positive results of the first nationwide clinical study showing the benefits of an antiangiogenic agent in breast cancer therapy are reported in the Dec. 27 issue of the New England Journal of Medicine.

28 Dec 2007

Bevacizumab found to improve survival for patients with advanced breast cancer

Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an anti-angiogenic therapy.

28 Dec 2007

Avastin shows promise for brain cancer

A clinical study conducted at Henry Ford Hospital on the use of a drug to extend the survival of patients with the most common and aggressive type of brain cancer, has yielded results that were significantly better than expected.

17 Dec 2007

Drug study for brain cancer shows promising results

14 Dec 2007

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007

New approaches to wet age-related macular degeneration treatment

Two particularly notable research presentations at the American Academy of Ophthalmology's Annual Meeting described new approaches to the treatment of "wet" Age-Related Macular Degeneration (AMD), the most common cause of severe vision loss in the western world in people over age 50.

13 Nov 2007

Bevacizumab improves ovarian cancer treatment

A new study appearing in International Journal of Gynecological Cancer states that Bevacizumab, a biologic anti-cancer agent that prevents tumor growth by interfering with the formation of new blood vessels, may have the potential to improve the efficacy of standard combination chemotherapy in ovarian cancer.

1 Nov 2007

Avastin and chemo combo may offer hope for glioblastoma multiforme patients

Brain cancer patients with the poorest prognosis -- those with a type of deadly tumor known as glioblastoma multiforme (GBM) -- may survive longer with a drug that chokes off a tumor's blood supply.

19 Oct 2007

Cancer trial combines multiple drugs to attack blood vessel formation in patients with kidney cancer

In the first clinical trial of its kind, researchers at the University of Pennsylvania School of Medicine and the Abramson Cancer Center will lead a nationwide test of anti-cancer drug combinations that target blood vessel growth in patients with advanced kidney cancer.

4 Oct 2007

New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas

Childhood brainstem gliomas (BSGs) are rare but can be very difficult to treat successfully and they tend to have poor survival rates.

26 Sep 2007

Avastin approved in Europe for advanced lung cancer

Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based chemotherapy.

26 Aug 2007

Chemotherapy with bevacizumab increases risk of blood clots in arteries

Treatment with chemotherapy and bevacizumab, an anticancer drug, is associated with a greater risk of blood clots in patients, arteries compared with treatment with chemotherapy only, according to a study published online August 7 in the Journal of the National Cancer Institute.

8 Aug 2007

St. Jude study holds promise for improving neuroblastoma treatment

A treatment for neuroblastoma that lands a one-two punch works best when the second punch is timed to take maximum advantage of the first one, according to results of studies at St. Jude Children's Research Hospital.

12 Jul 2007

A view on new drugs for macular degeneration

Restricting use of drugs for macular degeneration to patients who have already gone blind in one eye is "unacceptable" concludes the July issue of Drug and Therapeutics Bulletin (DTB).

4 Jul 2007

Study shows combination improves survival of metastatic melanoma patients

Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma, according to study findings presented at the 2007 American Association of Clinical Oncology (ASCO) Annual Meeting.

5 Jun 2007

Results of phase II studies of pazopanib

GlaxoSmithKline (GSK) has announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) and ovarian cancer.

5 Jun 2007